Jazz Pharmaceuticals plc Overview
Jazz Pharmaceuticals plc (JAZZ) has a ROE of 19.59%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow19.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Jazz Pharmaceuticals plc (JAZZ) currently reports a ROE of 19.59%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Jazz Pharmaceuticals plc's ROE history and peer comparisons.
Jazz Pharmaceuticals plc's ROE of 19.59% is higher than the Healthcare sector average of -100.59%. That is roughly 119.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Jazz Pharmaceuticals plc's current 19.59% should be judged against Healthcare norms (sector average: -100.59%) and against JAZZ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 19.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Jazz Pharmaceuticals plc, and consider following JAZZ for alerts when major investors trade the stock.
Jazz Pharmaceuticals plc is classified in the Healthcare sector. On ROE, it currently shows 19.59% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JAZZ with unrelated industries.
